Gland Pharma has announced its Q2 FY26 financial results, showcasing a 7% increase in revenue from operations, reaching ₹14,869 Mn. The company’s net profit (PAT) also saw a 12% rise, totaling ₹1,837 Mn. The results reflect continued growth in key markets and ongoing operational efficiencies. The company launched seven new molecules in the U.S. during the quarter.
Financial Performance Highlights
Gland Pharma’s Q2 FY26 consolidated financial results indicate sustained growth. Key highlights include:
- Revenue from operations: ₹14,869 Mn (up 7% year-over-year)
- Net Profit (PAT): ₹1,837 Mn (up 12% year-over-year)
- Gross Profit Margin: 63%
- EBITDA Margin: 21%
Segmental Performance
The company experienced growth across its core geographical segments:
- US Market: Saw a 10% year-over-year increase in group revenue contribution.
- Europe Market: Revenue increased by 22% year-over-year.
- Other Core Markets: Experienced a decline of 5% year-over-year.
Business Updates
Key business updates from Gland Pharma include:
- Launched seven molecules in the U.S., including Daptomycin-RTU and Sumatriptan.
- Filed six ANDAs and received approvals for five ANDAs in Q2 FY26.
- Total R&D expenses reached ₹614 million, representing 5.8% of revenue.
Cenexi Updates
Updates on Cenexi’s performance, with revenues impacted due to a planned shutdown:
- Revenue from operations: €40 Mn
- Gross Margin: 67%
Source: BSE